Articles published by Merck & Co., Inc.
US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
March 06, 2023
Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789
February 28, 2023
Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO™ (Molnupiravir)
February 24, 2023
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Regardless of PD-L1 Expression
February 16, 2023
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
February 02, 2023
Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO (fluralaner) Chews for Dogs
January 26, 2023
Merck Announces Second-Quarter 2023 Dividend
January 24, 2023
Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.
January 11, 2023
Merck to Hold Fourth-Quarter and Full-Year 2022 Sales and Earnings Conference Call February 2
January 05, 2023
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following